Historical perspective on the use of animal bioassays to predict carcinogenicity: Evolution in design and recognition of utility

Critical Reviews in Toxicology

Volumn 41, Issue 4, 2011, Pages 321-338

  Beyer, L A ^a   Beck, B D ^a   Lewandowski, T A ^a,b  

^a GRADIENT   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Animal bioassays; animal testing; cancer bioassays; chronic animal testing; historical analysis; US public health service

Indexed keywords

ALIPHATIC COMPOUND; AROMATIC AMINE; AROMATIC COMPOUND; BICYCLO COMPOUND; CARCINOGEN; CHEMICAL AGENT; CHLOROFORM; COSMETIC; DRUG; ENVIRONMENTAL CHEMICAL; INORGANIC COMPOUND; MELAMINE; NITROSAMINE; PERCHLORATE; PHENOBARBITAL; POLYCYCLIC AROMATIC HYDROCARBON; PURINE DERIVATIVE; QUINOLINE DERIVATIVE; VINYL CHLORIDE;

ANGIOSARCOMA; ANIMAL BIOASSAY; ANIMAL TESTING ALTERNATIVE; ANIMAL WELFARE; BIOASSAY; BLADDER TUMOR; CANCER CLASSIFICATION; CANCER RISK; CARCINOGENESIS; CARCINOGENICITY; DRUG MECHANISM; ENVIRONMENTAL EXPOSURE; EXPERIMENTAL ANIMAL; FOOD; HEALTH HAZARD; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; INDUSTRIALIZATION; LIVER TUMOR; METHODOLOGY; NONHUMAN; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; PUBLIC HEALTH SERVICE; RABBIT; REVIEW; RISK ASSESSMENT; SPECIES DIFFERENCE; TOXICITY TESTING; TOXICOKINETICS;

ANIMALS; ANIMALS, LABORATORY; BIOLOGICAL ASSAY; CARCINOGENICITY TESTS; CARCINOGENS; DISEASE MODELS, ANIMAL; ENVIRONMENTAL POLLUTANTS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; RISK ASSESSMENT;

ANIMALIA;

EID: 79953138734     PISSN: 10408444     EISSN: 15476898     Source Type: Journal    
DOI: 10.3109/10408444.2010.541222     Document Type: Review

References (164)

1. Albert RE. (1994). Carcinogen risk assessment in the U.S. Environmental Protection Agency. Crit Rev Toxicol 24:75-85. (Pubitemid 24122408)
2. Ames BN, Gold LS. (1990). Chemical carcinogenesis: Too many rodent carcinogens. Proc Natl Acad Sci USA 87:7772-7776. (Pubitemid 20341799)
3. Anderson MW, Hoel DG, Kaplan NL. (1980). A general scheme for the incorporation of pharmacokinetics in low-dose risk estimation for chemical carcinogenesis: Example - -Vinyl chloride. Toxicol Appl Pharmacol 55:154-161. (Pubitemid 10036702)
4. Backland S, Winder C, Khalil C, Hayes A. (2005). Toxicity assessment of industrial chemicals and airborne contaminants: Transition from in vivo to in vitro test methods: A review. Inhal Toxicol 17:775-787. (Pubitemid 41504537)
5. Baetcke KP, Hard GC, Rodgers IS, McGaughy RE, Tahan LM. (1991). Alpha2u-globulin: Association with Chemically Induced Renal Toxicity and Neoplasia in the Male Rat. Report to US Environmental Protection Agency, Washington, DC: Risk Assessment Forum. Report no. EPA/625/3-91/019F. September 1991.
6. Ballentine C. (1981). Taste of raspberries, taste of death: Te 1937 elixir sulfanilamide incident. FDA Consumer Magazine June
7. Bartsch H, Malaveille C. (1990). Screening assays for carcinogenic agents and mixtures: An appraisal based on data in the IARC monograph series. IARC Sci Publ 104:65-74.
8. Bartsch H, Tomatis L. (1983). Comparison between carcinogenicity and mutagenicity based on chemicals evaluated in the IARC monographs. Environ Health Perspect 47:305-317. (Pubitemid 13134671)
9. Beernaert H, Vanherle AM, Bertrand S. (2008). Critical aspects in implementing the OECD monograph No. 14 ""Te application of the principles of GLP to in vitro studies."." Ann Ist Super Sanita 44:348-356.
10. Bell DP, Elmes PC, Wheeler SM. (1964). A colony of specifc pathogen-free rats. Nature 201:273-274.
11. Benigni R, Zito R. (2004). Te second National Toxicology Program comparative exercise on the prediction of rodent carcinogenicity: Defnitive results. Mutat Res 566:49-63. (Pubitemid 38045588)
12. Boorman GA, Montgomery CA, Eustis SL, Wolf MJ, McConnell EE, Hardisty JF (1985). "Quality assurance in pathology for rodent carcinogenicity studies." In: Milman HA, Weisburger EK, eds. Handbook of Carcinogen Testing. HA Milman,and EK Weisburger (eds). Noyes Publications, Park Ridge, NJ.: Noyes Publications, pp. 345-357.
13. Boyland E. (1958). Te biological examination of carcinogenic substances. Br Med Bull 14:93-98.
14. Brenneman KA, Conolly RB, Gaido KW, Greenlee WF, Kimbell JS, Recio L. (2000). Research at CIIT on the health efects of exposure to chemicals. CIIT Activities 20:9-10.
15. Breslow L, Wilner D, Agran L, Breslow DL, Ellwein LB, Morganstern M, eds 1978 A History of Cancer Control in the United States 1946-1971: A History of Scientifc and Technical Advances in Cancer Control. Bethesda, MD: US Dept.artment of Health, Education, and Welfare, National Cancer Institute.
16. Butterworth BE. (1990). Consideration of both genotoxic and nongenotoxic mechanisms in predicting carcinogenic potential. Mutat Res 239:117-132.
17. Carson R. (1962). Silent Spring. Boston: Houghton Mifin.
18. Casanova M, Morgan KT, Steinhagen WH, Everitt JI, Popp JA, Heck HD. (1991). Covalent binding of inhaled formaldehyde to DNA in the respiratory tract of rhesus monkeys: Pharmacokinetics, rat-to-monkey interspecies scaling, and extrapolation to man. Fundam Appl Toxicol 17:409-428.
19. Case RAM, Hosker ME. (1954). Tumour of the urinary bladder as an occupational disease in the rubber industry in England and Wales. Br J Prev Soc Med 8:39-50.
20. Cogliano, VJ. 2006. Use of carcinogenicity bioassays in the IARC monographs. Ann. N Y Acad. Sci. 1076:592-600. (Pubitemid 44955289)
21. Cohen SM. (2001). Alternative models for carcinogenicity testing: Weight of evidence evaluations across models. Toxicol Pathol 29(Suppl):183-190.
22. Cohen SM, Klaunig J, Meek ME, Hill RN, Pastoor T, Lehman-McKeeman L, Bucher J, Longfellow DG, Seed J, Dellarco V, Fenner-Crisp P, Patton D. (2004). Evaluating the human relevance of chemically-induced animal tumors. Toxicol Sci 78:181-186. (Pubitemid 38559665)
23. Conolly RB, Reitz RH, Clewell HJ 3rd, Andersen ME. (1988). Pharmacokinetics, biochemical mechanism and mutation accumulation: A comprehensive model of chemical carcinogenesis. Toxicol Lett 43:189-200.
24. Counts JL, Goodman JI. (1995). Principles underlying dose selection for, and extrapolation from, the carcinogen bioassay: Dose infuences mechanism. Regul Toxicol Pharmacol 21:418-421.
25. Creech JL, Johnson MN. (1974). Angiosarcoma of liver in the manufacture of polyvinyl chloride. J Occup Med 16:150-151.
26. Dietz FK, Reitz RH, Watanabe PG, Gehring PJ. (1981). Translation of pharmacokinetic/biochemical data into risk assessment. Adv Exp Med Biol 136(Pt B):1399-1424.
27. Eastin WC. (1998). Te U.S. National Toxicology Program evaluation of transgenic mice as predictive models for identifying carcinogens. Environ Health Perspect 106(Suppl 1):81-4. (Pubitemid 28196038)
28. EFSA. (2006). Opinion of the Scientifc Panel on Food Additives, Flavourings, Processing Aids and Materials in Contact with Food (AFC) on a request from the Commission related to a new long-term carcinogenicity study on aspartame: Question number EFSA-Q-2005-122. Parma, Italy: European Food Safety Authority.
29. Ennever FK, Noonan TJ, Rosenkranz HS. (1987). Te predictivity of animal bioassays and short-term genotoxicity tests for carcinogenicity and non-carcinogenicity to humans. Mutagenesis 2:73-78. (Pubitemid 17045278)
30. Fairhall LT. (1952). Industrial toxicology: Dinitro-ortho-cresol. Occup Health (Auckl) 12:132-133.
31. FDA. (1959). Appraisal of the Safety of Chemicals in Foods, Drugs, and Cosmetics. Washington, DC: US Food and Drug Administration. Association of Food and Drug Ofcials of the United States.
32. FDA. (1978). Nonclinical laboratory studies: Good laboratory practice regulations. Fed Regist 43:59986-60025. US Food and Drug Administration. 21 CFR Part 58, December 22.
33. FDA. (2005). Milestones in US Food and Drug Law History. US Food and Drug Administration. Department of Health and Human Services. Available at: http://www.fda.gov/opacom/backgrounders/miles.html.
34. FDA. (2009). NCTR: A Look Back. US Food and Drug Administration. Available at: http://www.fda.gov/AboutFDA/ WhatWeDo/History/FOrgsHistory/NCTR/ ucm080414.htm.
35. FDA. (2010). Tolerances for Poisonous Ingredients in Food. Sec. 406. [21 USC § 346]. US Food and Drug Administration. Available at: http://www.fda.gov/RegulatoryInformation/Legislation/ FederalFoodDrugandCosmeticActFDCAct/FDCActChapterIVFood/ucm107545.
36. Fitzhugh OG, Nelson AA. (1946). Comparison of the chronic toxicity of triethylene glycol with that of diethylene glycol. J Ind Hyg Toxicol 28: 40-43.
37. Foran JA. (1997). Principles for the Selection of Doses in Chronic Rodent Bioassays. Washington, DC: ILSI Press.
38. Frederick WG. (1984). Te birth of the ACGIH Treshold Limit Values Committee and its infuence on the development of industrial hygiene. In: LaNier ME, ed. Annals of the American Conference of Governmental Industrial Hygienists,. Vol. 9. Cincinnati, OH: American Conference of Governmental Industrial Hygienists (ACGIH), 11-13.
39. Fung VA, Barrett JC, Huf J. (1995). Te carcinogenesis bioassay in perspective: Application in identifying human cancer hazards. Environ Health Perspect 103:680-683.
40. Gaylor DW. (1980). Te ED01 study: Summary and conclusions. J Environ Pathol Toxicol 3(3 Spec No):179-183.
41. Gaylor DW. (2005). Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens? Regul Toxicol Pharmacol 41:128-133. (Pubitemid 40187182)
42. Gaylor DW, Aylward LL. (2004). An evaluation of benchmark dose methodology for non-cancer continuous-data health efects in animals due to exposures to dioxin (TCDD). Regul Toxicol Pharmacol 40:9-17. (Pubitemid 38950882)
43. Gibson JE, Starr TB. (1988). Opportunities for improving techniques for interspecies extrapolation in the risk assessment process. Environ Health Perspect 77:99-105.
44. Gold LS, Slone TH, Ames BN. (1998). What do animal cancer tests tell us about human cancer risk?: Overview of analyses of the Carcinogenic Potency Database. Drug Metab Rev 30:359-404. (Pubitemid 28266868)
45. Goodman JI. (2001). A perspective on current and future uses of alternative models for carcinogenicity testing. Toxicol Pathol 29(Suppl):173-176.
46. Griesemer RA, Cueto C. (1980). Toward a classifcation scheme for degrees of experimental evidence for the carcinogenicity of chemicals for animals. In: Montesano R, Bartsch H, Tomatis L, eds. Molecular and Cellular Aspects of Carcinogen Screening Tests. IARC Scientifc Publications No. 27. Lyon, France: International Agency for Research on Cancer, 259-281. (Pubitemid 10023507)
47. Gruber FP, Hartung T. (2004). Alternatives to animal experimentation in basic research. ALTEX 1(Suppl 1):3-31. (Pubitemid 40074944)
48. Gulezian D, Jacobson-Kram D, McCullough CB, Olson H, Recio L, Robinson D, Storer R, Tennant R, Ward JM, Neumann DA. (2000). Use of transgenic animals for carcinogenicity testing: Considerations and implications for risk assessment. Toxicol Pathol 28:482-499. (Pubitemid 30394827)
49. Hackmann C. (1958). Problems of testing preparations for carcinogenic properties in the chemical industry. In: O′Connor O′,Connor M, ed. CIBA Foundation Symposium on Carcinogenesis Mechanisms of Action, Wolstenholme, GEW. Boston: Little, Brown and Co., 308-322.
50. Hadidian Z, Fredrickson TN, Weisburger EK, Weisburger JH, Glass RM, Mantel N. (1968). Tests for chemical carcinogens. Report on the activity of derivatives of aromatic amines, nitrosamines, quinolines, nitroalkanes, amides, epoxides, aziridines, and purine antimetabolites. J Natl Cancer Inst 41:985-1036.
51. Hall WE. (1951). Te industrial hazards of the organic phosphates and related insecticides, including parathion. Ann West Med Surg 5:1025-1027.
52. Hartwell JL. (1951). Survey of Compounds which have been Tested for Carcinogenic Activity. (Seco2nd edition). ([excerpts).]. Bethesda, MD: National Cancer Institute, 1-4, 546, 570.
53. Haseman JK. (1985). Issues in carcinogenicity testing: Dose selection. Fundam Appl Toxicol 5:66-78. (Pubitemid 15164316)
54. Hayes, AW, ed. (2008). Principles and Methods of Toxicology. (Fif5th edition). Philadelphia, PA: Taylor & Francis.
55. Hoenerhof MJ, Hong HH, Ton TV, Lahousse SA, Sills RC. (2009). A review of the molecular mechanisms of chemically induced neoplasia in rat and mouse models in National Toxicology Program bioassays and their relevance to human cancer. Toxicol Pathol 37:835-848.
56. Höfer T, Gerner I, Gundert-Remy U, Liebsch M, Schulte A, Spielmann H, Vogel R, Wettig K. (2004). Animal testing and alternative approaches for the human health risk assessment under the proposed new European chemicals regulation. Arch Toxicol 78:549-564. (Pubitemid 39591625)
57. Holsapple MP, Pitot H, Cohen SH, Boobis AR, Klaunig JE, Pastoor T, Dellarco VL, Dragan YP. (2006). Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci 89:51-56. (Pubitemid 43013754)
58. Hueper WC. (1957). Newer developments in occupational and environmental cancer. Arch Intern Med 100:487-503.
59. Hueper WC, Wiley FH, Wolfe HD, Ranta KE, Leming MF, Blood FR. (1938). Experimental production of bladder tumors in dogs by administration of betanaphthylamine. J Ind Hyg Toxicol 20:46-84.
60. IARC. (1972). IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man,. Vol. 1. Lyon: International Agency for Research on Cancer., World Health Organization.
61. IARC. (1979). IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans: Vol. 20. Some Halogenated Hydrocarbons,. Vol 20. Lyon, International Agency for Research on Cancer., World Health Organization.
62. IARC. (1979). IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans: Some Halogenated Hydrocarbons, Volume 20. World Health Organization (WHO).
63. IARC. (1980). IARC Monographs, Supplement 2: Long-Term and Short-Term Screening Assays for Carcinogens: A Critical Appraisal. Lyon: International Agency for Research on Cancer., World Health Organization.
64. IARC. (1987). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs, Volumes 1 to 42, Supplement 7. Lyon: International Agency for Research on Cancer., World Health Organization.
65. IARC. (1991). IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans: Vol. 53. Occupational Exposures in Insecticide Application, and Some Pesticides. Lyon: International Agency for Research on Cancer., World Health Organization.
66. ICH. (1997). S1B: Testing for Carcinogenicity of Pharmaceuticals. International Conference on HarmonizationHarmonisation. Available at: http://www.ich.org/LOB/media/MEDIA490.pdf.
67. Innes JRM, Ulland BM, Valerio MG, Petrucelli L, Fishbein L, Hart ER, Palotta AH, Bates RR, Falk HL, Gart JJ, Klein M, Mitchell I, Peters J. (1969). Bioassay of pesticides and industrial chemicals for tumorigenicity in mice: A preliminary note. J Natl Cancer Inst 42:1101-1115.
68. JECFA. (1958). Procedures for the Testing of Intentional Food Additives to Establish their Safety for Use: Second Report of the Joint FAO/WHO Expert Committee on Food Additives. Rome: Joint FAO/WHOExpert Committee on Food Additives., World Health Organization.
69. WHO Technical Report Series No. 144. Junod S. (1999). Te rise and fall of federal food standards in the United States: Te case of the peanut butter and jelly sandwich. Presented at Society for the Social History of Medicine., Spring conference, Aberdeen, Scotland. April 9.
70. Kalberer JT, Newell GR. (1979). Funding impact of the National Cancer Act and beyond. Cancer Res 39:4274-4284.
71. Keplinger ML, Goode JW, Gordon DE, Calandra JC. (1975). Interim results of exposure of rats, hamsters, and mice to vinyl chloride. Ann N Y Acad Sci 246:219-224.
72. Kerns WD, Pavkov KL, Donofrio DJ, Gralla EJ, Swenberg JA. (1983). Carcinogenicity of formaldehyde in rats and mice after long-term inhalation exposure. Cancer Res 43:4382-4392. (Pubitemid 13041877)
73. King-Herbert A; Tayer K. (2006). NTP workshop: Animal models for the NTP rodent cancer bioassay: Stocks and strains-Should we switch? Toxicol.Pathol. 34:802-805.
74. Lane-Petter W. (1962). Te provision and use of pathogen-free animals. Proc R Soc Med 55:253-256.
75. Lane-Petter W. (1970). A ventilation barrier to the spread of infection in laboratory animal colonies. Lab Anim 4:125-134.
76. Legator MS, Ward JB Jr. (1991). Use of in vivo genetic toxicity data for risk assessment. Mutat Res 250:457-65.
77. Lehman AJ. (1951). Proof of safety: Some interpretations. J Am Pharm Assoc 11:305-308.
78. Lehman AJ, Laug EP, Woodard G, Draize JH, Fitzhugh OG, Nelson AA. (1949). Procedures for the appraisal of the toxicity of chemicals in foods. Food Drug Cosmet Q 4:412-433.
79. Lehman AJ, Patterson WI, Davidow B, Hagan EC, Woodard G, Laug EP, Frawley JP, Fitzhugh OG, Bourke AR, Draize JH, Nelson AA, Vos BJ. (1955). Procedures for the appraisal of the toxicity of chemicals in foods, drugs, and cosmetics. Food Drug Cosmet Law J 10:679-748.
80. Long GG, Morton D, Peters T, Short B, Skydsgaard M. (2010). Alternative mouse models for carcinogenicity assessment: Industry use and issues with pathology interpretation. Toxicol Pathol 38:43-50.
81. Lutz WK. (1991). Dose-response relationships in chemical carcinogenesis: From DNA adducts to tumor incidence. Adv Exp Med Biol 283:151-156.
82. Malarkey D, Herbert R, Nyska A, Sutphin M, Pernicka K. [National Toxicology Program (NTP)]. (2010). Internal correspondence to J. Bucher (NTP) re: report on visit (4/25/2010 -4/30/2010) and assessment of the pathology procedures performed at the Ramazzini Institute, Bentivoglio, Italy. June 11.
83. Maltoni C, Lefemine G. (1974a). [Experiments testing the carcinogenic potential of vinyl chloride.] Rendiconti (Accademia nazionale dei Lincei. Classe di scienze fsiche, matematiche e naturali). 56:1-15.
84. Maltoni C, Lefemine G. (1974b). Carcinogenicity bioassays of vinyl chloride. I. Research plan and early results. Environ Res 7:387-405.
85. Maltoni C, Lefemine G. (1975). Carcinogenicity bioassays of vinyl chloride. Current results. Ann N Y Acad Sci 246:195-218.
86. Mantel N, Bryan WR. (1961). Safety testing of carcinogenic agents. J Natl Cancer Inst 27:455-471.
87. Maron DM, Ames BN. (1983). Revised methods for the Salmonella mutagenicity test. Mutat. Res. 113 (3-4):173-215. (Pubitemid 13120319)
88. Mauderly JL, Jones RK, Grifth WC, Henderson RF, McClellan RO. (1987). Diesel exhaust is a pulmonary carcinogen in rats exposed chronically by inhalation. Fundam Appl Toxicol 9:208-221.
89. McCann J, Choi E, Yamasaki E, Ames BN. (1975) Detection of carcinogens as mutagens in the Salmonella/microsome test: Assay of 300 chemicals. Proc. Natl. Acad. Sci. USA 72 (12):5135-5139.
90. McConnell EE, Solleveld HA, Swenberg JA, Boorman GA. (1986). Guidelines for combining neoplasms for evaluation of rodent carcinogenesis studies. J Natl Cancer Inst 76:283-289. (Pubitemid 16130010)
91. Meek ME, Bucher JR, Cohen SM, Dellarco V, Hill RN, Lehman-McKeeman LD, Longfellow DG, Pastoor T, Seed J, Patton DE. (2003). A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol 33:591-653. (Pubitemid 38040084)
92. Munro IC. (1977). Considerations in chronic toxicity testing: Te chemical, the dose, the design. J Environ Pathol Toxicol 1:183-197.
93. Murray JA. (1922). Te production of cancer by specifc forms of irritation. Br Med J 2:1103-1104.
94. NCI. (2007a). Cancer Facts and the War on Cancer. National Cancer Institute. Division of Cancer Cause and Prevention. Available at: http://training.seer.cancer.gov/disease/war/.
95. NCI. (2007b). Artifcial Sweeteners and Cancer. National Cancer Institute. Available at: www.cancer.gov/cancertopics/factsheet/Risk/artifcial-sweeteners
96. Nelson AA, Fitzhugh OG, Calvery HO. (1943). Liver tumors following cirrhosis caused by selenium in rats. Cancer Res 3:230-236.
97. Nelson AA, Fitzhugh OG, Calvery HO. (1945). Production of bladder stones and bladder tumors in rats by feeding of diethylene glycol. Fed Proc Fed Am Soc Exp Pathol 4:149.
98. Nioi P, Pardo ID, Sherratt PJ, Snyder RD. (2008). Prediction of non-genotoxic carcinogenesis in rats using changes in gene expression following acute dosing. Chem Biol Interact 172:206-215.
99. NIOSH. (1996). NIOSH Celebrates 25th Anniversary. National Institute for Occupational Safety and Health. Available at: http://www.cdc. gov/Niosh/updates/twenff.html. Accessed on 16 December 2008.
100. NRC. (1983). Risk Assessment in the Federal Government: Managing the Process. National Research Council. Committee on the Institutional Means for Assessment of Risks to Public Health. Washington, DC: National Academies Press.
101. NRC. (2007). Toxicity Testing in the Twenty-First Century: A Vision and a Strategy. National Research Council. Division on Earth and Life Studies, Board on Environmental Studies and Toxicology and Institute for Laboratory Animal Research. Washington, DC: National Academies Press.
102. NRC. (2009). Science and Decisions: Advancing Risk Assessment. National Research Council. Committee on Improving Risk Analysis Approaches Used by the U.S. EPA. Washington, DC: National Academies Press.
103. NTP. (1984). Report of the NTP Ad Hoc Panel on Chemical Carcinogenesis Testing and Evaluation. Research Park Triangle, NC: National Toxicology Program.
104. NTP. (2004). History of the NTP. National Toxicology Program. Available at: http://ntp.niehs.nih.gov/?objectid=720163C9-BDB7-CEBA-FE4B970B9E72BF54.
105. NTP. (2006). Eleventh Report on Carcinogens. National Toxicology Program. US Department of Health and Human Services, Public Health Service. Available at: http://ntp.niehs.nih.gov/index. cfm?objectid=32BA9724-F1F6-975E- 7FCE50709CB4C932.
106. OECD. (2009a). OECD Test Guideline 453: Combined Chronic Toxicity\/Carcinogenicity Studies. Organisation for Economic Co-operation and Development. OECD 453. Available at: http://www.oecdilibrary.org/oecd/content/ book/9789264071223-en. Accessed on 16 December 2008.
107. OECD. (2009b). OECD Guidelines for Testing of Chemicals: Full List of Test Guidelines. Organisation for Economic Co-operation and Development. Available at: http://www.oecd.org/dataoecd/8/11/42451771.pdf.
108. Page NP. (1977). Chronic toxicity and carcinogenicity guidelines. J. Environ. Pathol. Toxicol 1(2):161-182.
109. Patty FA, Yant WP, Waite CP. (1930). Acute response of guinea pigs to vapors of some new commercial organic compounds. V. Vinyl chloride. Public Health Rep 45:1963-1971.
110. Peto R, Gray R, Brantom P, Grasso P. (1991). Efects on 4080 rats of chronic ingestion of N-nitrosodiethylamine or N-nitrosodimethylamine: A detailed dose-response study. Cancer Res 51:6415-6451.
111. Portier CJ. (1993). Mechanistic modeling and risk assessment. Pharmacol Toxicol 72(Suppl 1):28-32.
112. Rall DP. (1984). Te National Toxicology Program. In: Tegeris AS, ed. Toxicology Laboratory Design and Management for the 80′s 80′s and Beyond. Concepts in Toxicology, Vol. 1. Basel, Switzerland: Karger, 283-293.
113. Rall DP. (2000). Laboratory animal tests and human cancer. Drug Metab Rev 32:119-128. (Pubitemid 30198551)
114. Reed DJ. (1991). Future research needs for the application of mechanistic data to risk assessment. Adv Exp Med Biol 283:863-868.
115. Rhomberg LR, Baetcke K, Blancato J, Bus J, Cohen S, Conolly R, Dixit R, Doe J, Ekelman K, Fenner-Crisp P, Harvey P, Hattis D, Jacobs A, Jacobson-Kram D, Lewandowski T, Liteplo R, Pelkonen O, Rice J, Somers D, Turturro A, West W, Olin S. (2007). Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: Approaches to dose selection. Crit Rev Toxicol 37:729-837. (Pubitemid 350034876)
116. Rodricks JV. (1988). Origins of risk assessment in food safety decision making. J Am Coll Toxicol 7:539-542.
117. Roe FJ. (1980). Current methods in testing for carcinogenic activity. Br J Cancer. 41:495-496.
118. Rohwer SA, Haller HL, Dubois K, Grob D, Abrams HK, Hamblin DC, Marchand JF, Lehman AJ, Hartzell A, Ward JW. (1950). Pharmacology and toxicology of certain organic phosphorus insecticides; general description of their activity and usefulness; pharmacology; toxicology; clinical experience; efects on benefcial forms of life, crops and soil and residue hazards. J Am Med Assoc 144:104-108.
119. Sacquet E. (1965). Pathogen-free animals. Food Cosmet Toxicol 3:47-55.
120. Schwetz B, Gaylor D. (1997). New directions for predicting carcinogenesis. Mol Carcinog 20:275-279. (Pubitemid 127468297)
121. Selling L. (1916). Benzol as leucotoxin. Studies on the degeneration and regeneration of the blood and haematopoietic organs. Johns Hopkins Hosp Rep 17:83-149.
122. Shubik P, Hartwell JL. (1957). Survey of Compounds which have been Tested for Carcinogenic Activity: Supplement 1. Washington, DC: US Government Printing Ofce.
123. Shubik P, Hartwell JL. (1969). Survey of Compounds which have been Tested for Carcinogenic Activity: Supplement 2. Washington, DC: US Government Printing Ofce.
124. Sofriti M, Belpoggi F, Minardi F, Maltoni C. (2002). Ramazzini Foundation Cancer Program: History and major projects, life span carcinogenicity bioassay design, chemicals studies, and results. Ann N Y Acad Sci 982:26-45 (Pubitemid 36127070)
125. Sofritti M, Belpoggi F, Tibaldi E, Esposti DD, Lauriola M. (2007) Life-span exposure to low doses of aspartame beginning during prenatal life increases cancer efects in rats. Environ Health Perspect 115(9):1293-1297. (Pubitemid 47471252)
126. Sontag JM, Page NP, Safotti U. (1976). Guidelines for Carcinogen Bioassay in Small Rodents. Report to US Dept.artment of Health, Education and Welfare. Springfeld, VA: National Technical Information Service. Report no. NTIS PB-264061, NCI-CG-TR-1.
127. SOT. (1981). Re-examination of the ED01 study. Review of statistics: Te need for realistic statistical models for risk assessment. Society of Toxicology: ED01 Task Force. Fundam Appl Toxicol 1:124-126.
128. Starr TB. (1985). Te role of mechanistic data in dose-response modeling. Basic Life Sci 33:101-124.
129. Starr TB, Buck RD. (1984). Te importance of delivered dose in estimating low-dose cancer risk from inhalation exposure to formaldehyde. Fundam Appl Toxicol 4:740-753. (Pubitemid 15184894)
130. Starr TB, Gibson JE. (1985). Te mechanistic toxicology of formaldehyde and its implications for quantitative risk estimation. Annu Rev Pharmacol Toxicol 25:745-767. (Pubitemid 15091001)
131. Swenberg JA, Kerns WD, Mitchell RI, Gralla EJ, Pavkov KL. (1980). Induction of squamous cell carcinomas of the rat nasal cavity by inhalation exposure to formaldehyde vapor. Cancer Res 40(9):3398-3402. (Pubitemid 10043560)
132. Swenberg JA, Richardson FC, Boucheron JA, Deal FH, Belinsky SA, Charbonneau M, Short BG. (1987). High- to low-dose extrapolation: Critical determinants involved in the dose response of carcinogenic substances. Environ Health Perspect 76:57-63. (Pubitemid 18075923)
133. Tennant RW, Spalding J, French JE. (1996). Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mutat Res 365:119-127. (Pubitemid 26344742)
134. Tomas RS, Bao W, Chu TM, Bessarabova M, Nikolskaya T, Nikolsky Y, Andersen ME, Wolfnger RD. (2009). Use of short-term transcriptional profles to assess the long-term cancer-related safety of environmental and industrial chemicals. Toxicol Sci 112:311-321.
135. Tomas RS, O′Connell O′Connell TM, Pluta L, Wolfnger RD, Yang L, Page TJ. (2007). A comparison of transcriptomic and metabonomic technologies for identifying biomarkers predictive of two-year rodent cancer bioassays. Toxicol Sci 96:40-46. (Pubitemid 46323207)
136. Tomatis L. (1979). Te predictive value of rodent carcinogenicity tests in the evaluation of human risks. Annu Rev Pharmacol Toxicol 19:511-530. (Pubitemid 9156589)
137. Tomatis L. (1986). Foreword. In: Montesano R, Bartsch H, Vainio H, Wilbourn J, Yamasaki H, eds. Long-Term and Short-Term Assays for Carcinogens: A Critical Appraisal. International Agency for Research on Cancer (IARC) Scientifc Publication No. 83, p1. Lyon: IARC.
138. Tsutsui H. (1918). "[Short summary of the original essay: On the artifcial cancer produced in mice]. GANN 12:17-21.
139. UCB, Gold LS. (2008). Te carcinogenic potency database (CPDB). University of California, Berkeley. Available at: http://potency. berkeley.edu/.
140. US EPA. (1976). Health risk and economic impact assessments of suspected carcinogens: Interim procedures and guidelines. Fed Regist 41(1102):21402-21405.
141. US EPA. (1980). Te Carcinogen Assessment Group′s Group′s List of Carcinogens. Washington, DC: Carcinogen Assessment Group. Report no. EPA 450/R-80-104. July 1980.
142. US EPA. (1986a). Guidelines for Carcinogen Risk Assessment. Washington, DC: Carcinogen Assessment Group. Report no. EPA/630/R-00/004. September 1986.
143. US EPA. (1986b). Guidelines for Mutagenicity Risk Assessment. Washington, DC: Risk Assessment Forum. Report no. EPA/630/R-98/003. September 1986.
144. US EPA. (1986). Guidelines for Mutagenicity Risk Assessment. Washington, DC: Risk Assessment Forum. Report no. EPA/630/R-98/003. September 1986.
145. US EPA. (1991a). Guidelines for Developmental Toxicity Risk Assessment. Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum, Washington, DC,. EPA/600/FR-91/001,. 1991.
146. US EPA. (1991b). Report of the EPA Peer Review Workshop on Alpha2u-Globulin: Association with Renal Toxicity and Neoplasia in the Male Rat. Washington, DC: Risk Assessment Forum. Report no. EPA/625/3-91/021.
147. US EPA. (1996). Guidelines for Reproductive Toxicity Risk Assessment. Washington, DC: Risk Assessment Forum. Report no. 630/R-96/009.
148. US EPA. (2005). Guidelines for Carcinogen Risk Assessment (Final). Washington, DC: Risk Assessment Forum. Report no. EPA/630/P-03/001F.
149. US EPA. (2006). Harmonization in Interspecies Extrapolation: Use of BW3/4 as Default Method in Derivation of the Oral RfD. External Review Draft Report no. EPA/630/R-06/001. February 2006.
150. US EPA. (2009). Risk Assessment Forum Publications List. Ofce of the Science Advisor. Available at: http://www.epa.gov/raf/pubyear.htm. Accessed on 7 June 2010.
151. US EPA. (2010). News Release: EPA Places Four IRIS Assessments on Hold Pending Review. Available at: http://yosemite.epa.gov/opa/admpress.nsf/0/ B64D44F06A56D5B285257742007C5002. Accessed on 15 June 2010.
152. US PHS. (1941-2000). Survey of Compounds Which Have Been Tested for Carcinogenic Activity. US Public Health Service Pub. lication No. 149. US Public Health Service, National Cancer Institute. Washington, DC: US Government Printing Ofce.
153. Vainio H. (1994). Use of mechanistic and other data in identifying carcinogens: A review based on the IARC Monographs programme. Arch Toxicol Suppl. 16:281-294.
154. Ward JM, Goodman DG, Griesemer RA, Hardisty JF, Schueler RL, Squire RA, Strandberg JD. (1978) Quality assurance of pathology in rodent carcinogenesis tests. J. Environ Pathol Toxicol Oncol. 2:371-378 (Pubitemid 9246954)
155. Wax PM. (1995). Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act. Ann Intern Med 122:456-461.
156. Weisburger EK. (1983). History of the bioassay program of the National Cancer Institute. Prog Exp Tumor Res 26:187-201.
157. Weisburger JH, Weisburger EK. (1967). Tests for chemical carcinogens. In: Busch H, ed. Methods in Cancer Research,. Volume Vol. I. New York: Academic Press, 307-398.
158. Weisburger JH. (1994). Does the Delaney clause of the U.S. food and drug laws prevent human cancers? Fund. am Appl. Tox. icol 22:483-493.
159. Weisburger JH. (1999). Carcinogenicity and mutagenicity testing, then and now. Mutation Research 437:105-112. (Pubitemid 29518292)
160. Williams GM, Iatropoulos MJ, Weisburger JH. (1996). Chemical carcinogen mechanisms of action and implications for testing methodology. Exp Toxicol Pathol 48:101-111. (Pubitemid 26078637)
161. Woodard G, Calvery HO. (1943). Acute and chronic toxicity: Public health aspects. Ind Med 12:55-59.
162. Yamagiwa K, Ichikawa K. (1915). Ueber die kunstliche erzeugung von papillom (German)=[On the experimental induction of papillomas.] [German]. Verh Jpn Pathol Ges 5:142-149.
163. Yamagiwa K, Ichikawa K. (1918). Experimental study of the pathogenesis of carcinoma. J Cancer Res 3:1-29.
164. Zapp JA, Doull J. (1994). Industrial toxicology: Retrospect and prospect. In: Patty′s Patty′s Industrial Hygiene and Toxicology. Fourth 4th editioned., Volume Vol. II, Part A. New York: Wiley and Sons, 1-24.